Creative innovation, leading the future. 2020 Health Industry High Quality Development Conference and the 5th China Pharmaceutical Research and Development and Innovation Summit Expert Style.

Introduction: The next decade, China's preparation industry golden decade.
September 10, 2020 Health Industry High Quality Development Conference and the 5th China Pharmaceutical Research and Development innovation summit (PDI) in Chongqing Marriott Hotel grand opening, 10-11, around the theme of "preparation innovation, leading the future", the Conference divided into drug preparation innovation and development forum, preparation development key technology seminars, slow release agent development key technology discussion forum, from the national hundred experts and scholars.
opening ceremony site, the uity rate of new preparations in China is less than 5%, far below the global average, the industry has broad prospects for development.
with the upgrading of pharmaceutical consumption, the use of new preparations is an inevitable trend, China's new preparation market will show explosive development.
domestic preparation field has ushered in a ten-year golden period of industry development, how to improve the innovation ability of preparations, quickly keep up with the international level? What are the key factors in the development of new preparations? Hundreds of experts from the conference site held a comprehensive and in-depth discussion on these issues.
, the top: the direction of drug innovation at the beginning of this year, the new pharmaceutical regulations began to implement, including pharmaceutical production capacity, imported medicinal herbs, import duties, health insurance and other 11 new regulations.
will drug innovation face under the new regulations and what opportunities will it bring? Professor Chen Zhen, a professor at Zhengzhou University School of Pharmacy and a researcher at Shenyang Pharmaceutical University's Yihong Business School, proposed the drug management law implemented in 2019, including the drug registration management measures implemented in July this year, a series of drug regulation laws and regulations, aimed at building a system of drug life cycle management based on the principle of scientific risk, and there are many major breakthroughs in the regulatory system for the registration of innovative drugs.
to respect the law of drug research and development, promote patient-oriented balanced value, strengthen risk management as the grasping drug life cycle management, to drug innovation provides unprecedented opportunities, China's innovative drugs will be better and better.
professor Chen Zhen, a professor at Zhengzhou University's School of Pharmacy and a researcher at Shenyang Pharmaceutical University's Yihong Business School, said in a report on "The Project and Research Strategy of Improved New Drugs" from the perspective of early clinical exploration and research of innovative drugs.
hope that the pharmaceutical industry to have a long-ended attitude to do drugs, taking full account of legal feasibility, clinical feasibility, intellectual property feasibility, market feasibility and other factors.
Professor Yang Jin of the Pharmaceutical Research Center of China Pharmaceutical University, Mr. Lai Caida, General Manager of Hangzhou Pharmaceutical Technology Co., Ltd., has deeply analyzed the current situation of the development of new pharmaceutical preparations driven by artificial intelligence with the theme of "Artificial Intelligence Drives the Development of New Pharmaceutical Preparations" and introduced the research and development strategy of the second class of new drugs.
that preparation research and development can not be separated from the support of advanced technology, one of the most important tools is artificial intelligence.
Hangzhou Agent Thai Pharmaceutical Technology Co., Ltd. General Manager Lai Caida II, outline: preparation research and development is the key Shandong Baino Pharmaceutical Co., Ltd. preparation research and development director Dr. Wang Jinyuan brought the "crystallization process research and sharing" theme report, he explained the impact of drug crystalline research on preparations, pointed out the significance of drug crystalline research, as well as the impact of drug solid form on preparation research, in which innovative preparation research and development has become a key problem facing the pharmaceutical and chemical industry.
Shandong Baino Pharmaceutical Co., Ltd. director of preparation research and development, Dr. Wang Jinyuan, Guangzhou Bosco Control and Interpretation Pharmaceutical Co., Ltd. vice president of preparation, Dr. Li Wei made a report on "the analysis of key factors to improve the level of comprehensive research and development of preparations", in the form of practical cases to share his experience and lessons, pointed out the key factors to improve the level of comprehensive research and development of preparations.
Dr. Li Wei, Vice President of Preparations of Guangzhou Bostra Pharmaceutical Co., Ltd., and Jiang Ma, Chief Engineer of Southwest Pharmaceuticals, brought the theme report "Process Amplification in Injection Research and Development", pointing out that injections play an important role in clinical drug use and pharmaceutical industrial production.
the process amplification of injections and the sharing of process and equipment in conventional injection forms from the perspective of producer, production line and engineering practice.
li Tianquan, director of Taiji Group, co-founder of Southwest Pharmaceuticals, president of the Pharmaceutical Intelligence Elite Club, editor-in-chief of China Pharmaceutical Research and Development 40 Years of Pharmaceutical Big Data, and senior engineer, brought a speech on the theme of "One Wave and Three Folds of China's Dispersed Tablets Research and Development", which put forward the real significance of dispersing tablets from its definition and clinical significance, emphasizing the real significance of improving patient compliance in generics.
Pharmaceutical Intelligence Network co-founder, president of the Pharmaceutical Intelligence Elite Club, editor-in-chief of "China Pharmaceutical Research and Development 40 Years of Pharmaceutical Big Data", senior engineer Li Tianquan Nanjing Jiqun Pharmaceutical Co., Ltd. General Manager, Chief Technical Officer Wu Xiaotao took us in-depth understanding of the "improved new drug research and development strategy and practice", for you to share the real case of improved new drugs and generic drugs, from the new prescription process, compliance changes and other aspects of the emphasis on the choice of research and development strategy.
Dr. Li Zhengqi, General Manager and Chief Technology Officer of Nanjing Jiqun Pharmaceutical Co., Ltd., made the theme report of "Clinical Trial Program Design for Complex Preparations", analyzed the clinical trial cases of various reagents on the spot, and showed the importance and necessity of program design through the sharing of failure cases.
National Lighting Pharmaceutical Technology Co., Ltd. Chairman Dr. Li Zhengqi III, international perspective: high-end preparations to look ahead to the domestic, the main preparation research and development is still a simple oral solid preparation, for high-end preparations with high barriers to research and development technology is still very few.
problems face in the development of high-end preparations? How to move forward from the global cutting-edge technology and seize key opportunities? On-site experts and scholars to carry out in-depth discussion.
First of all, Sun Asia, the main founder of Hunan Jingye Pharmaceutical Technology and Beijing Yaxin Baocheng Pharmaceutical Technology Co., Ltd., gave a keynote speech on "Analysis and Technology Sharing of New Drug Preparations Research and Development Case", emphasizing the importance of API and ginseng design in drug preparation research and development, and demonstrated in many ways.
Hunan Jingye Pharmaceutical Technology, Beijing Yaxin Baocheng Pharmaceutical Technology Co., Ltd. main founder Sun Asia Chongqing Kangzhou Big Data Co., Ltd. Research Institute Vice President Dr. Liu Zhongwei brought "through the data to see the global slow release of preparation trends", pointed out that the current pharmaceutical industry by the volume of procurement and consistent evaluation of the overall impact of drug supervision of the new regulations supporting the introduction of demand, and pointed out the industry's basic competition of the three strategies.
Chongqing Kangzhou Big Data Co., Ltd. Research Institute Vice President Dr. Liu Zhongwei Hangzhou Xinhai Pharmaceutical Technology Co., Ltd. Deputy General Manager Luo Ruichang made a "peptide product development difficulties and ideas to explore" the theme of the report, pointed out that the market huge polypeptide drug advantages are obvious, but the key to its consistency evaluation lies in easy to ignore the research and development technology.
Hangzhou Xinhai Pharmaceutical Technology Co., Ltd. Deputy General Manager Luo Ruichang Chongqing Pharmaceutical Friends President Assistant Professor Lei Wangshing brought the "World Pharmaceutical Industry Trends" keynote speech, he believes that the world pharmaceutical industry growth tends to moderate, the scale growth rate of 5%, in a small number of enterprises monopolize most of the market, the future of pharmaceutical companies will be more frequent acquisitions, pointing out the driving factors of innovation for the development of the pharmaceutical industry.
Chongqing Pharmaceutical Friends President Assistant Professor Lei Wangshua Professor Fahrenheit Kangyuan International Division General Manager Mr. Li Bin, on the "New Situation of Clinical Research" made a keynote report, analyzed the past domestic clinical research difficulties, pointed out that the future development of small and medium-sized CRO companies will be around the company's specialization.
, general manager of The Fahrenheit Kangyuan International Business Unit, comprehensive layout: Special preparations to meet the opportunity It is understood that with China's aging, as well as the acceleration of urbanization process, the incidence of respiratory diseases is on the rise.
special preparations such as inhalation and drugation, the market is rising rapidly with the advantages of quick effect and fewer side effects.
First of all, Professor Hou Shuguang, Vice President of Bett Pharmaceutical Group and General Manager of Four Trump Reed Pharmaceuticals, brought the theme report "Inhalation Preparation Development Strategy", which outlines the risks and benefits of the preparation development process from several real-world cases. Professor Hou Shuguang, Vice President of
-Times Pharmaceutical Group and General Manager of Four Trump Reit Pharmaceuticals, made a keynote report on "Research and Development Progress of Mitochondrial Targeting System" by Professor Huang Yuan, Party Secretary of Huaxi Pharmaceutical College of Sichuan University, which brought us the results of the international first-line "Mitochondrial Targeting Research", emphasizing that the gap between ideal and reality in the field is still huge, and calling on experts from all walks of life to work together to create a new environment for information exchange.
Professor Huang Yuan, Party Secretary of Huaxi Pharmaceutical College of Sichuan University, Vice President of Beijing Yingkerui Innovative Pharmaceutical Co., Ltd. and General Manager of Yingkerui (Tianjin) brought the theme report of "Atomized Inhalation Preparation Technology and Case Sharing" to atomize inhalation preparations, innovative research and development points and specific cases to share three major parts of the atomized inhalation preparations of strong clinical value.
Vice President of Beijing Yingkerui Innovative Pharmaceutical Co., Ltd., Chairman of Yingkerui (Tianjin) General Manager Hu Jie ChangshaDuZheng Biotech Co., Ltd., Professor of Clinical Pharmacology Institute of Xiangya Hospital, Central South University, And Professor Ouyang Dongsheng, Ph.D. Tutor, delivered a keynote speech on "Difficulties and Solutions in the Study of High-Variation Drugs and PPI BE" and introduced the international guidelines for high-variation drugs, the differences between the European Union and the United States.
the importance of controlling BE and drug metabolism for highly mutant drugs.
ChangshaDuZheng Biotech Co., Ltd. Chairman, Central South University Xiangya Hospital Institute of Clinical Pharmacology Professor, doctoral tutor Professor Ouyang Dongsheng five, go hand in hand: solid preparations to promote as one of the important components of the preparation - solid preparations, its common dosage forms have dispersants, granules, tablets, capsules, pills, film agents, etc., in the pharmaceutical preparations about 70%, good physical and chemical stability, production costs are low, easy to take.
often because of the production process by the production line production process, technical bottlenecks and other reasons, resulting in the quality of drugs is not qualified.
Zhou Xiaotang, Senior Director of The Preparation Department of Shanghai Medici Biopharmaceutical Co., Ltd., made a keynote speech on the application of fixed dispersion technology in rapid release and slow-control release preparations, saying that the application of solid dispersion technology can improve the solubility or solubility of the drug, so that the rate of drug dissolution and biological utilization rate have been significantly improved.
Professor Wang Jianxin, Senior Director of The Preparation Department of Shanghai Medici Biopharmaceutical Co., Ltd., brought the keynote speech of "Micro-Pill Tablet Technology and Application" to explain the many advantages of micro-pill tablets and the characteristics and advantages of micro-pill tablet technology.
Wang Jianxin, Vice Dean of Fudan University School of Pharmacy, Professor Lei Jifeng, Chairman of Shanghai Anbisheng Pharmaceutical Technology Co., Ltd., made the theme report of "The parameters and control of membrane control tablet coating process", how to wrap from a process point of view, pointing out that in order to achieve uniformity of coating, more from the engineering point of view.
Reuter Dr. Wei Shifeng, Co-Founder and General Manager of Beijing Rono Qiangshi Pharmaceutical Technology Research and Development Center Co., Ltd., Chairman of Shanghai Anbisheng Pharmaceutical Technology Co., Ltd., delivered the keynote speech of "Research Strategies for Solid Preparations for Insoluble Drugs".
that insoluble drugs are high-tech barrier products, research and development should consider whether to comply with the development strategy of new pharmacy, avoid organic solvents and so on.
Dr. Wei Shifeng, Co-Founder and General Manager of Beijing Rono Qiangshi Pharmaceutical Technology Research and Development Center Co., Ltd., Dr. Liu Feng, Chairman and General Manager of Guangzhou Diqi Pharmaceutical Technology Co., Ltd., delivered the keynote speech "Prescription Process Development and Industrialization of Skeleton Tablets", in which he introduced the variety of skeleton preparations, prescription process development and industrialization, and the advantages of new skeleton tablets compared to traditional skeletons.
Guangzhou Diqi Pharmaceutical Technology Co. , Ltd. Chairman and General Manager Dr. Liu Feng 6, on-site dialogue: facing up to the difficult situation at the same time, the General Assembly specially arranged Professor Wang Jianxin, Professor Ouyang Dongsheng, Professor Yang Jin and Dr. Liu Feng 4 experts on-site dialogue, Jian refers to the bottleneck of innovative drug development, and strive to get rid of the current adverse situation of innovative drugs.
7, the world: hand in hand with the new era In recent years, China's pharmaceutical research and development growth rate has leapt to the first in the world, innovation output and capacity to rapidly improve, new drug research and development investment in the field of unprecedented enthusiasm, the domestic continuous emergence of a number of innovative research and development strength of enterprises.
Conference released the "2020 China Pharmaceutical Research and Development Strength Rankings" (this list is the 5th since 2016), the series of lists include "2020 China Pharmaceutical Research and Development Comprehensive Strength Ranking TOP100" "2020 China Pharmaceutical Research and Development Strength Top 100" 2020 China Biopharmaceity Research and Development Strength Ranking TOP50, 2020 China Chinese Medicine Research and Development Strength Ranking TOP50, and 2020 China Research and Development CRO Enterprise 20, 2020 China CDMO Enterprise Top 20, and on-site awards for the award-winning enterprises.
100 award ceremony, the scene also carried out the opening ceremony of the pharmaceutical intelligence think tank.
resources are one of the most valuable resources of the country, the nation and mankind, and the realization of each national strategy can not be separated from think tanks to play an important role.
Pharmaceutical intelligence think tank by the Pharmaceutical Intelligence Network as the main sponsor, pooling the pharmaceutical industry's top expert resources, committed to the government, parks, investment and financing institutions, large enterprises and other units, to provide strategic advice, decision-making consulting, project demonstration and a series of high-end intelligent output services.
boost economic development for the country and regions, and make positive contributions to the pharmaceutical and health industry and enterprise-driven innovation.
China Pharmaceutical Industry Online Publishing Launch Ceremony was held on the spot, and the online edition of "China Pharmaceutical Industry" was officially launched.
Zhao Yong, a member of the party group and deputy director of the Chongqing Municipal Drug Administration, and Tang Hua, president of china Pharmaceutical Magazine, took the stage to participate in the launch ceremony, which was presided over by Liu Bin, editor-in-chief of China Pharmaceutical Magazine.
"China Pharmaceutical Industry" online publishing launch ceremony is worth mentioning, in response to the call of national policy, to achieve the complementary advantages of The two places, pharmaceutical industry cooperation, sing a good "Double City", build a "Chengyu Economic Circle", the General Assembly ad hoc "Chengyu Double City Economic Circle Pharmaceutical Industry Integration and Development Summit Forum."
The forum was organized by the Chengdu High-tech District Bio-Industry Development Bureau and the Great Health Industry Development Promotion Center of The South Bank District of Chongqing, with the participation of relevant government leaders, industry association leaders, industry experts and pharmaceutical enterprise leaders from Chengdu and Chongqing.
10%.